{"0239.HK": {"short_name": "PAK FAH YEOW", "long_name": "Pak Fah Yeow International Limited", "summary": "Pak Fah Yeow International Limited, an investment holding company, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People's Republic of China, Southeast Asia, North America, the United Kingdom, and internationally. It operates through three segments: Healthcare, Property Investments, and Treasury Investments. The company offers white flower embrocation medicated oils, strain relief products, and ointments under the under the Hoe Hin brand name, as well as F\u00c3\u00bazai 239, a floral-scented white flower embrocation. In addition, it invests in commercial, industrial, residential, and car park properties; and provides advertising agency services. Pak Fah Yeow International Limited is headquartered in Wan Chai, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "0241.HK": {"short_name": "ALI HEALTH", "long_name": "Alibaba Health Information Technology Limited", "summary": "Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical e-commerce, intelligent medicine, and product tracking platform businesses in the People's Republic of China. It engages in business-to-customer (B2C) retail activities; advertisement business; and business-to-business (B2B) centralized procurement distribution business. The company also provides pharmaceutical and healthcare products through its online stores on Tmall.com and offline pharmacy outlets to B2C and B2B customers; marketing services; health consultation services; outsourced and value-added services to the Tmall entities; and telemedicine services. In addition, it trades in pharmaceutical products; and provides network hospital services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. The company is based in Causeway Bay, Hong Kong. Alibaba Health Information Technology Limited is a subsidiary of Perfect Advance Holding Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Causeway Bay"}, "0286.HK": {"short_name": "AIDIGONG", "long_name": "Aidigong Maternal & Child Health Limited", "summary": "Aidigong Maternal & Child Health Limited, an investment holding company, provides postpartum care and healthcare services in the People's Republic of China. It operates through Postpartum Care Services, Health Industry, and Other segments. The company offers maternal and child healthcare services; medical anti-aging services; healthcare industry investment services; and healthcare property development services, as well as trades in natural health food and pharmaceutical products. It also offers precision life healthcare, bio-medical technology, management, and aesthetic and beauty treatment services, as well as investment and finance services. The company was formerly known as Common Splendor International Health Industry Group Limited and changed its name to Aidigong Maternal & Child Health Limited in December 2019. Aidigong Maternal & Child Health Limited was incorporated in 1990 and is based in Kowloon Bay, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Kowloon Bay"}, "0401.HK": {"short_name": "WANJIA GROUP", "long_name": "Wanjia Group Holdings Limited", "summary": "Wanjia Group Holdings Limited, an investment holding company, engages in pharmaceutical wholesale and distribution business in the People's Republic of China and Hong Kong. It also offers hemodialysis treatment and consultancy services. The company sells its products to hospitals and healthcare institutions; and companies operating pharmaceutical retail chain stores, independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics in Fujian province. Wanjia Group Holdings Limited was founded in 2004 and is headquartered in Kowloon, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Distribution", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Kowloon"}, "0455.HK": {"short_name": "TIANDA PHARMA", "long_name": "Tianda Pharmaceuticals Limited", "summary": "Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese and western medicines and biochemical drugs, etc., such as cardio-cerebrovascular drugs, pediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, detoxification agents, and other pharmaceutical products. The company offers its health care products under the Herb Valley brand name. It also engages in the sale and wholesale of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicines; property holding business; provision of Chinese medical services; and trading of agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "0460.HK": {"short_name": "SIHUAN PHARM", "long_name": "Sihuan Pharmaceutical Holdings Group Ltd.", "summary": "Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company offers cardio-cerebral vascular system, central nervous system, metabolism, anti-infective, oncology, and digestive drugs. It also engages in the marketing of pharmaceutical products; manufacture of pharmaceutical materials; project preparation for the manufacture of pharmaceutical products; sale of medical appliances; promotion of technology and consulting services; and construction of medical projects, as well as the provision of information support, research and development, business and development, and general hospital and hospital management services. In addition, the company provides import and export trade services; and markets aesthetic medicines. Additionally, it invests in property; constructs environmental protection projects; and wholesales medical devices raw materials. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical Holdings Group Ltd. is a subsidiary of Plenty Gold Enterprises Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "0574.HK": {"short_name": "PASHUN INT'L", "long_name": "Pa Shun International Holdings Limited", "summary": "Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution activities in the People's Republic of China. It operates through Pharmaceutical Distribution, Self-Operated Retail Pharmacies, and Pharmaceutical Manufacturing segments. The Pharmaceutical Distribution segment sells pharmaceutical products to wholesalers, franchise retail pharmacy chain stores, and hospitals and other medical institutions in rural areas. The Self-Operated Retail Pharmacies segment engages in the sale of pharmaceutical and healthcare products, cosmetic products, and daily necessities in self-operated retail pharmacies. The Pharmaceutical Manufacturing segment sells pharmaceutical products manufactured by the company. It also engages in the plantation of biological assets; distribution of Chinese herbal medicines; and operation of a medicine chain store. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is based in Kwun Tong, Hong Kong. Pa Shun International Holdings Limited is a subsidiary of Praise Treasure Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Kwun Tong"}, "0690.HK": {"short_name": "UNI-BIO GROUP", "long_name": "Uni-Bio Science Group Limited", "summary": "Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and distribution of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It offers prescription drugs, including Uni-E4, a recombinant rExendin-4 injection for the treatment of Type 2 diabetes; and Uni-PTH, an injection form of recombinant human parathyroid hormone for the treatment of osteoporosis in postmenopausal women. The company also provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF-derivative eye drop for corneal damage and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. Uni-Bio Science Group Limited was founded in 2001 and is headquartered in Shatin, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Shatin"}, "0722.HK": {"short_name": "UMP", "long_name": "UMP Healthcare Holdings Limited", "summary": "UMP Healthcare Holdings Limited, an investment holding company, provides a range of medical and healthcare services in the People's Republic of China. It operates through two segments, Corporate Healthcare Solution Services and Clinical Healthcare Services. The company offers virtual care; family medicine; specialist consultation services, including internal medicine, surgery, pediatrics, cardiology, dermatology, otorhinolaryngology, orthopedics, ophthalmology, urology, gastroenterology and hepatology, radiology, endocrinology, and diabetes; and dental care services, such as dental implant, cosmetic dentistry, periodontal treatments, and orthodontics, as well as traditional Chinese medicines. It also provides physiotherapy services comprises muscle-strengthening, limb function, eye-hand coordination, and hand function trainings; day surgery and endoscopy; diagnostic imaging and laboratory; health assessment; visa medical examination; vaccination and consultation; vision care and optometry; plastic, head, and neck surgeries; dermatology and aesthetics; chronic disease management; and child health and development services. In addition, the company engages in the provision of day surgery, endoscopy, and healthcare training services. It serves insurance companies and corporations, and self-paid patients. As of June 30, 2020, the company operated a network of approximately 800 self-owned and affiliated service points. UMP Healthcare Holdings Limited was founded in 1990 and is headquartered in Central, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "0876.HK": {"short_name": "KAISA HEALTH", "long_name": "Kaisa Health Group Holdings Limited", "summary": "Kaisa Health Group Holdings Limited, an investment holding company, manufactures and trades in dental prosthetics in the People's Republic of China and internationally. The company offers dental prosthetics, including crowns and bridges, removable full and partial dentures, implants, and full-cast restorations, as well as public health and medical services. It is also involved in the investment holding of convertible promissory note, as well as medical technology development and consultation service. The company was formerly known as Mega Medical Technology Limited and changed its name to Kaisa Health Group Holdings Limited in January 2018. Kaisa Health Group Holdings Limited was founded in 1971 and is headquartered in Central, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "0897.HK": {"short_name": "WAI YUEN TONG", "long_name": "Wai Yuen Tong Medicine Holdings Limited", "summary": "Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. The company offers Chinese medicines and health food products under the Wai Yuen Tong brand name; and western pharmaceutical and personal care products under the Madame Pearl's and Pearl's brands. It also engages in the investment, holding, and selling of properties; provision of financial services; and agricultural produce exchange market operation. It operates approximately 55 retail stores in Hong Kong. The company was founded in 1897 and is headquartered in Kowloon Bay, Hong Kong. Wai Yuen Tong Medicine Holdings Limited is a subsidiary of Rich Time Strategy Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Kowloon Bay"}, "0907.HK": {"short_name": "ELEGANCEOPTICAL", "long_name": "Elegance Optical International Holdings Limited", "summary": "Elegance Optical International Holdings Limited, an investment holding company, manufactures and trades in optical frames and sunglasses in the United States, Europe, the People's Republic of China, other Asian countries, and internationally. The company operates through four segments: Manufacturing and Trading, Property Investment, Debts and Securities Investment, and Film Investment and Distribution. It is also involved in property leasing and investment businesses; securities investment activities; investing in financial instruments and quoted shares; money lending and loan financing activities; film right and movie investment and distribution activities; and trading of bags. The company was formerly known as Elegance International Holdings Limited and changed its name to Elegance Optical International Holdings Limited in September 2013. Elegance Optical International Holdings Limited was founded in 1975 and is headquartered in Wan Chai, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "0911.HK": {"short_name": "QIANHAI HEALTH", "long_name": "Qianhai Health Holdings Limited", "summary": "Qianhai Health Holdings Limited, an investment holding company, engages in the sale of health products in Hong Kong. It operates through Health-Care Products and Electronic Component Products segments. The company offers Chinese herbal medicines, and skin-care and other health-care products to wholesalers and retailers. It offers American ginseng, an herbaceous perennial plant, which includes cultivated and wild ginseng; and ginseng wine. The company is also involved in the sale of information technology components, such as central processing units and semi-conductors. In addition, it engages in the property and other assets holding, and property leasing activities; and money lending business through the provision of secured and unsecured loans. The company was formerly known as Hang Fat Ginseng Holdings Company Limited and changed its name to Qianhai Health Holdings Limited in September 2016. The company was founded in 1989 and is based in Sheung Wan, Hong Kong. Qianhai Health Holdings Limited is a subsidiary of Explorer Rosy Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Sheung Wan"}, "1061.HK": {"short_name": "ESSEX BIO-TECH", "long_name": "Essex Bio-Technology Limited", "summary": "Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu eye drops for various corneal defects and punctate keratopathy, recurrent punctate keratopathy in the shallow layer, dry eye, corneal operation and poor corneal healing after the operation, geographic herpes simplex keratitis, and ballous keratitis, as well as for corneal abrasion, mild, and moderate chemical burns; and Beifushu eye gels to treat corneal transplantation and eye surface reconstruction, dry eye, cataract surgery, and corneal refractive surgery, as well as to treat various keratopathy, ocular traumas, and foreign body removal. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties; and eye health care products, including Beifu shuhui capsules to treat fundus ocular diseases, asthenopia, and visual impairments. Further, the company distributes Carisolv, a product for the treatment of root caries, deep cavities, and dental caries, as well as for removing carious dentin tissues. Essex Bio-Technology Limited has a research collaboration agreement with AC Immune SA to develop a biological therapeutic for the treatment of neurodegenerative diseases, such as Alzheimer's disease; and license agreement with Mitotech S.A. and Mitotech LLC. Essex Bio-Technology Limited was founded in 1999 and is headquartered in Central, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "1134.HK": {"short_name": "KELFRED", "long_name": "Kelfred Holdings Limited", "summary": "Kelfred Holdings Limited, an investment holding company, manufactures and sells eyewear products. It produces a range of spectacle frames and sunglasses primarily through original design manufacturing and original equipment manufacturing business models. The company also offers original brand manufacturing products under the Miga brand. Its services include product design and development, raw materials procurement, production, quality control, packaging, and delivery. The company is operates in Italy, the United Kingdom, the Netherlands, Hong Kong, France, Spain, Hungary, the United States, and internationally. Kelfred Holdings Limited was founded in 1986 and is headquartered in Sha Tin, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Sha Tin"}, "1498.HK": {"short_name": "PURAPHARM", "long_name": "PuraPharm Corporation Limited", "summary": "PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mailand China, and internationally. The company operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. It offers holistic products under the PuraGold, Haveron, CardioClear, PuraPharm Lingzhi, and Arashi Kuni names; and various therapeutic products under the Nong's, Oncozac, and Immuzac names for Chinese medicine practitioners. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and concentrated Chinese medicine granules (CCMG) products. In addition, the company engages in the plantation and trading of raw Chinese herbs; and manufacture and sale of traditional Chinese medicine decoction pieces. Further, it researches, develops, and trades in modernized Chinese medicines; and provides Chinese medical diagnostic services. The company sells its products to hospitals, medical institutions, and medicine practitioners, as well as operates an online store. As of December 31, 2019, the company operated 67 Nong's clinics in Hong Kong and 1 Nong's clinic in Guangxi, China. The company was founded in 1998 and is headquartered in Central, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "1612.HK": {"short_name": "VINCENT MED", "long_name": "Vincent Medical Holdings Limited", "summary": "Vincent Medical Holdings Limited, an investment holding company, researches, develops, manufactures, markets, and sells medical devices. It operates in two segments, Original Equipment Manufacturing (OEM) and Original Brand Manufacturing. The company develops medical devices focusing on respiratory products; imaging contrast media power injector disposables; and orthopedic and rehabilitation products for OEM customers. Its respiratory products portfolio includes humidification systems, nCPAP interface systems, respiratory care units, electronic air-oxygen blenders, and anesthesia systems. The company's orthopedic and rehabilitation products comprise various adjustable rehabilitation braces for support and protection, and rehabilitation of various skeletomuscular parts after injury or surgery. It also develops robotic hand training devices. Vincent Medical Holdings Limited sells its products under the Inspired Medical, Hand of Hope, and Hypnus brand names in the People's Republic of China, the United States, the Netherlands, Australia, Japan, and internationally. The company was founded in 1997 and is headquartered in Hung Hom, Hong Kong. Vincent Medical Holdings Limited is a subsidiary of Vincent Raya International Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Hung Hom"}, "2005.HK": {"short_name": "SSY GROUP", "long_name": "SSY Group Limited", "summary": "SSY Group Limited, an investment holding company, researches, develops, manufactures, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; and food, beverages, and catering business. It sells its products under Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was incorporated in 2004 and is headquartered in Wanchai, Hong Kong. SSY Group Limited is a subsidiary of China Pharmaceutical Co., Ltd.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "2189.HK": {"short_name": "KATO (HK) HLDGS", "long_name": "Kato (Hong Kong) Holdings Limited", "summary": "Kato (Hong Kong) Holdings Limited operates residential care homes for the elderly in Hong Kong. The company provides a range of residential care services for the elderly, including accommodation, professional nursing and care-taking, nutritional management, medical, physiotherapy and occupational therapy, psychological and social care, individual care, and recreational services; and sells healthcare and medical goods, as well as offers add-on healthcare services to its residents. As of March 31, 2020, it operated eight care and attention homes for the elderly with 1,129 residential care places across four districts in Hong Kong under the Fai To, Kato, Happy Luck Home, Tsuen Wan Centre, and Pine Villa brand names. The company was founded in 1991 and is based in Tuen Mun, Hong Kong. Kato (Hong Kong) Holdings Limited is a subsidiary of Sheung Fung Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Tuen Mun"}, "2293.HK": {"short_name": "BAMBOOSHEALTH", "long_name": "Bamboos Health Care Holdings Limited", "summary": "Bamboos Health Care Holdings Limited, an investment holding company, provides healthcare staffing solution services in Hong Kong. It offers 24-hour private nursing services; home care and consultation solutions; nursing and rehabilitation assessment; and physiotherapy and occupational therapy solutions. The company also provides healthcare personnel and healthcare staffing solutions; and marketing and consulting services, as well as operates aesthetic clinic. It serves individuals and institutional clients, including hospitals, social service organizations, and clinics. The company was founded in 2009 and is headquartered in Tsim Sha Tsui, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Tsim Sha Tsui"}, "2348.HK": {"short_name": "DAWNRAYS PHARMA", "long_name": "Dawnrays Pharmaceutical (Holdings) Limited", "summary": "Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics; and system specific medicines for various therapeutic areas comprising cardiovascular system, anti-allergic, anti-HBV, digestive system, urinary system, anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "2633.HK": {"short_name": "JACOBSON PHARMA", "long_name": "Jacobson Pharma Corporation Limited", "summary": "Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures and trades in generic drugs and proprietary medicines in Hong Kong, China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including respiratory, cardiovascular, central nervous system, gastrointestinal, scar treatment, and oral anti-diabetics, anti-infective, diltiazem controlled release, dihydrocodeine, perindopril tablets. propranolol oral solution, mesalazine enteric coated tablets 500mg and finasteride tablets dermatological, and anti-allergic drugs. It also provides proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan/Shiling oil, and Col-gan tablet. In addition, it trades in medical supplies. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Kwun Tong"}, "3309.HK": {"short_name": "C-MER EYE", "long_name": "C-MER Eye Care Holdings Limited", "summary": "C-MER Eye Care Holdings Limited, an investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and the People's Republic of China. The company operates eye and surgery centers, and satellite clinics that provide cataract and intraocular lens implant, refractive correction, corneal and external eye disease, glaucoma, vitreo-retinal disease, oculoplastic and orbital disease, and squint and pediatric ophthalmology services. It also sells vision aid and pharmaceutical products. The company was founded in 2012 and is headquartered in Central, Hong Kong. C-MER Eye Care Holdings Limited is a subsidiary of C-MER Group Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "3390.HK": {"short_name": "TYCOON GROUP", "long_name": "Tycoon Group Holdings Limited", "summary": "Tycoon Group Holdings Limited, an investment holding company, distributes a suite of health and well-being related products in Hong Kong, Mainland China, Macau, and Singapore. It operates through Distribution, Retail Stores, and Online Stores segments. The company offers proprietary Chinese medicine, health supplement, skin care, personal care, and other healthcare products under the third-party and private label brands. It sells its products to chain retailers, non-chain retailers, and traders; and individual customers through two brick-and-mortar retail stores and online stores. The company was founded in 2015 and is headquartered in Shatin, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Shatin"}, "3600.HK": {"short_name": "MODERN DENTAL", "long_name": "Modern Dental Group Limited", "summary": "Modern Dental Group Limited, an investment holding company, produces and distributes dental prosthetic devices in Europe, Greater China, North America, Australia, and internationally. It operates through three segments: Fixed Prosthetic Devices, Removable Prosthetic Devices, and Others. The Fixed Prosthetic Devices segment offers metal-ceramic crowns and bridges, metal crowns and bridges, metal-free crowns and bridges, and custom implant abutments devices. The Removable Prosthetic Devices segment provides removable dentures. The Others segment offers orthodontic devices, sports guards, anti-snoring devices, raw materials, and dental equipment. This segment also provides services for educational events and seminars. The company sells its products to dentists, dental clinics, hospitals, distributors, and other customers under the Permadental & Semperdent, Elysee, Labocast, Modern Dental Laboratory, Yangzhijing, Southern Cross Dental, Andent, Gold & Ceramics, Precision Dental, Modern Dental USA, MicroDental, Sundance Dental, Quantum Dental, Labo Ocean Indien, and Digitek Dental brands. Modern Dental Group Limited was founded in 1986 and is based in Kowloon, Hong Kong. Modern Dental Group Limited is a subsidiary of Triera Holdings Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Kowloon"}, "3613.HK": {"short_name": "TONGRENTANGCM", "long_name": "Beijing Tong Ren Tang Chinese Medicine Company Limited", "summary": "Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates in three segments: Hong Kong, PRC, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates 71 retail outlets in 20 countries and regions. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wanchai, Hong Kong. Beijing Tong Ren Tang Chinese Medicine Company Limited is a subsidiary of Tong Ren Tang Technologies Co., Ltd.", "currency": "HKD", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "3681.HK": {"short_name": "SINOMAB BIO-B", "long_name": "SinoMab BioScience Limited", "summary": "SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a BTK inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, NHL, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China and Hong Kong. SinoMab BioScience Limited was founded in 2001 and is headquartered in Pak Shek Kok, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Tai Po"}, "6CB.F": {"short_name": "GLOBAL CORD BLOOD DL-0001", "long_name": "Global Cord Blood Corporation", "summary": "Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Central"}, "8143.HK": {"short_name": "GF HEALTHCARE", "long_name": "Good Fellow Healthcare Holdings Limited", "summary": "Good Fellow Healthcare Holdings Limited, an investment holding company, provides general hospital services in Mainland China and internationally. Its general hospital services include medical and surgical wards, and medical checkup and examination. As of March 31, 2020, the company operated three general hospitals in Jiaxing, Zhuhai, and Beijing. It also provides medical investment and hospital management services. The company was formerly known as Hua Xia Healthcare Holdings Limited and changed its name to Good Fellow Healthcare Holdings Limited in February 2019. The company was incorporated in 2001 and is headquartered in Central, Hong Kong. Good Fellow Healthcare Holdings Limited is a subsidiary of Solar Star Global Limited.", "currency": "HKD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "8622.HK": {"short_name": "HUAKANG BIOMED", "long_name": "Huakang Biomedical Holdings Company Limited", "summary": "Huakang Biomedical Holdings Company Limited, a medical device company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wan Chai"}, "9969.HK": {"short_name": "INNOCARE-B", "long_name": "InnoCare Pharma Limited", "summary": "InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It is developing Orelabrutinib (ICP-022), a Bruton's tyrosine kinase that is in registrational trials for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma; in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. Its preclinical stage products include ICP-723, a pan-inhibitor of tropomyosin-related kinase family to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-330, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was founded in 2015 and is headquartered in Wanchai, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wanchai"}, "ALBHF": {"short_name": "ALIBABA HEALTH INFORMATION TECH", "long_name": "Alibaba Health Information Technology Limited", "summary": "Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical e-commerce, intelligent medicine, and product tracking platform businesses in the People's Republic of China. It engages in business-to-customer (B2C) retail activities; advertisement business; and business-to-business (B2B) centralized procurement distribution business. The company also provides pharmaceutical and healthcare products through its online stores on Tmall.com and offline pharmacy outlets to B2C and B2B customers; marketing services; health consultation services; outsourced and value-added services to the Tmall entities; and telemedicine services. In addition, it trades in pharmaceutical products; and provides network hospital services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. The company is based in Causeway Bay, Hong Kong. Alibaba Health Information Technology Limited is a subsidiary of Perfect Advance Holding Limited.", "currency": "USD", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Causeway Bay"}, "CO": {"short_name": "Global Cord Blood Corporation", "long_name": "Global Cord Blood Corporation", "summary": "Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).", "currency": "USD", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "NYQ", "market": "us_market", "country": "Hong Kong", "city": "Central"}, "HCM": {"short_name": "Hutchison China MediTech Limite", "long_name": "Hutchison China MediTech Limited", "summary": "Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "Hong Kong", "city": "Central"}, "HCM.L": {"short_name": "HUTCHISON CHINA MEDITECH LIMITE", "long_name": "Hutchison China MediTech Limited", "summary": "Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.", "currency": "GBp", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "LSE", "market": "gb_market", "country": "Hong Kong", "city": "Central"}, "MSIU": {"short_name": "MEDICAL SUPPLY INTL USA INC", "long_name": "Medical Supply International USA, Inc.\t", "summary": "Medical Supply International USA, Inc., together with its subsidiaries, provides rehabilitation services and specialized hospital services in the healthcare industry in the People's Republic of China. It operates rehabilitative center, and maternity and specialized service hospital. The rehabilitative center serves patients who have survived from a serious injury or illness or an addiction and are seeking therapeutic or medical treatment. The company also operates outpatient clinic and offers other services, including private outpatients and health check-up services, and obstetrics and gynecology services. It offers 4-D ultrasound system applications for scanning for medical purposes, IPL system applications for treatment various kinds of skin disorder, and cosmetic surgery. The company was formerly known as Master Spirit International USA Inc. and changed its name to Medical Supply International USA, Inc. in October 2018. Medical Supply International USA, Inc. was founded in 2001 and is headquartered in Wan Chai, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wan Chai"}, "SBHMY": {"short_name": "SINO BIOPHARMACEUTICAL", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wan Chai"}, "SBMFF": {"short_name": "SINO BIOPHARMACEUTICAL", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wan Chai"}, "SHPHF": {"short_name": "SIHUAN PHARMACEUTICAL HOLD GP L", "long_name": "Sihuan Pharmaceutical Holdings Group Ltd.", "summary": "Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company offers cardio-cerebral vascular system, central nervous system, metabolism, anti-infective, oncology, and digestive drugs. It also engages in the marketing of pharmaceutical products; manufacture of pharmaceutical materials; project preparation for the manufacture of pharmaceutical products; sale of medical appliances; promotion of technology and consulting services; and construction of medical projects, as well as the provision of information support, research and development, business and development, and general hospital and hospital management services. In addition, the company provides import and export trade services; and markets aesthetic medicines. Additionally, it invests in property; constructs environmental protection projects; and wholesales medical devices raw materials. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical Holdings Group Ltd. is a subsidiary of Plenty Gold Enterprises Limited.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wan Chai"}, "SKYI": {"short_name": "SKY CENTURY INVESTMENT INC", "long_name": "Sky Century Investment, Inc.", "summary": "Sky Century Investment, Inc., a development stage company, intends to find and manage new music talents and bands in China. The company was formerly known as Band Rep Management, Inc. and changed its name to Sky Century Investment, Inc. in May 2017. The company was founded in 2012 and is based in Tsim Sha Tsui, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Tsim Sha Tsui"}, "SMIF.F": {"short_name": "CHINA MED.+HLTH.G.HD-0005", "long_name": "China Medical & HealthCare Group Limited", "summary": "China Medical & HealthCare Group Limited, an investment holding company, primarily operates hospitals in the Hong Kong and People's Republic of China. It operates through six segments: Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments. The company is also involved in the property development of independent living units; and project management of health campus with a focus on elderly care and retirement community comprising elderly nursing homes, service apartments, and independent living units, as well as a shopping mall, retail shops, and club hall facilities. In addition, it develops and sells properties and land; leases residential and office properties; and provides money lending, financial and strategic investment, and healthcare services. Further, the company is involved in trading of medical equipment and related supplies. Additionally, it invests and trades in securities. The company is also involved in trading of securities listed in overseas exchange. The company was formerly known as COL Capital Limited and changed its name to China Medical & HealthCare Group Limited in February 2016. The company is headquartered in Wanchai, Hong Kong.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}, "SMZ1.F": {"short_name": "SINO BIOPH.SUBDIV.HD-,025", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}, "SMZU.F": {"short_name": "SINO BIOPHARM. UNS.ADR/20", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}, "TBET": {"short_name": "TIBET PHARMACEUTICALS INC", "long_name": "Tibet Pharmaceuticals, Inc.", "summary": "Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women's anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission. The company also develops Xuezang Guben pill indicated for the treatment of neurasthenia, insomnia, frequent urination, nocturnal emission, and women's menopausal symptoms; Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B. In addition, it focuses to commercialize Wupeng Pill for treating echimococosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. The company was formerly known as Shangri-La Tibetan Pharmaceuticals, Inc. and changed its name to Tibet Pharmaceuticals Inc. in July 2010. Tibet Pharmaceuticals, Inc. is headquartered in Wanchai, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Drugs - Generic", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wanchai"}, "TEL1.F": {"short_name": "SIHUAN PHARMAC.GRP HD-,01", "long_name": "Sihuan Pharmaceutical Holdings Group Ltd.", "summary": "Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company offers cardio-cerebral vascular system, central nervous system, metabolism, anti-infective, oncology, and digestive drugs. It also engages in the marketing of pharmaceutical products; manufacture of pharmaceutical materials; project preparation for the manufacture of pharmaceutical products; sale of medical appliances; promotion of technology and consulting services; and construction of medical projects, as well as the provision of information support, research and development, business and development, and general hospital and hospital management services. In addition, the company provides import and export trade services; and markets aesthetic medicines. Additionally, it invests in property; constructs environmental protection projects; and wholesales medical devices raw materials. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical Holdings Group Ltd. is a subsidiary of Plenty Gold Enterprises Limited.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}, "TQR.F": {"short_name": "BEIJ.TONG R.T.CHIN.", "long_name": "Beijing Tong Ren Tang Chinese Medicine Company Limited", "summary": "Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates in three segments: Hong Kong, PRC, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates 71 retail outlets in 20 countries and regions. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wanchai, Hong Kong. Beijing Tong Ren Tang Chinese Medicine Company Limited is a subsidiary of Tong Ren Tang Technologies Co., Ltd.", "currency": "EUR", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}, "TWY.F": {"short_name": "ALIBABA HLTH INFO.T.HD-01", "long_name": "Alibaba Health Information Technology Limited", "summary": "Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical e-commerce, intelligent medicine, and product tracking platform businesses in the People's Republic of China. It engages in business-to-customer (B2C) retail activities; advertisement business; and business-to-business (B2B) centralized procurement distribution business. The company also provides pharmaceutical and healthcare products through its online stores on Tmall.com and offline pharmacy outlets to B2C and B2B customers; marketing services; health consultation services; outsourced and value-added services to the Tmall entities; and telemedicine services. In addition, it trades in pharmaceutical products; and provides network hospital services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. The company is based in Causeway Bay, Hong Kong. Alibaba Health Information Technology Limited is a subsidiary of Perfect Advance Holding Limited.", "currency": "EUR", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Causeway Bay"}, "TWY.SG": {"short_name": "Alibaba Health Inform.Tech.LtdR", "long_name": "Alibaba Health Information Technology Limited", "summary": "Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical e-commerce, intelligent medicine, and product tracking platform businesses in the People's Republic of China. It engages in business-to-customer (B2C) retail activities; advertisement business; and business-to-business (B2B) centralized procurement distribution business. The company also provides pharmaceutical and healthcare products through its online stores on Tmall.com and offline pharmacy outlets to B2C and B2B customers; marketing services; health consultation services; outsourced and value-added services to the Tmall entities; and telemedicine services. In addition, it trades in pharmaceutical products; and provides network hospital services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. The company is based in Causeway Bay, Hong Kong. Alibaba Health Information Technology Limited is a subsidiary of Perfect Advance Holding Limited.", "currency": "EUR", "sector": "Healthcare", "industry": "Pharmaceutical Retailers", "exchange": "STU", "market": "dr_market", "country": "Hong Kong", "city": "Causeway Bay"}, "UNJ.F": {"short_name": "UNITED LABS INTL  HD -,01", "long_name": "The United Laboratories International Holdings Limited", "summary": "The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings and organic fertilizers; holds trademarks; trades in pharmaceutical products; and engages in the food production activities. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, Hong Kong, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited is a subsidiary of Heren Far East Limited.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Yuen Long"}}